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Abstract  
Background: Hemolysis is common in malaria infection and during the course of 
treatment. Previous studies have reported delayed post-artemisinin hemolysis occurring 
in naïve and immune individuals treated with parenteral or oral artemisinin-derivatives. 
This study aims to understand if delayed hemolysis occurs in the absence of malaria 
parasites and the underlying mechanisms for the hemolytic effects after administration of 
two antimalarial drugs to malaria-free Wistar rats. Methods: Forty animals were 
randomized into 5 groups of eight animals each; they received 4 mg/kg artesunate for 7 
days (AS), 4 mg/kg artesunate plus 10mg/kg amodiaquine for 3 days (ASQ), 10mg/kg 
amodiaquine for 3 days (AQ), distilled water [normal control], (Control) and 1mg/kg 
phenylhydrazine for 1 day to induce hemolysis (PHZ) groups respectively. Packed cell 
volume (PCV), white blood cell differential count and serum haptoglobin (Hpt) levels 
were determined in all groups on day 4 and 18 to detect hemolysis. Mean values were 
compared using t-test and ANOVA with p values < 0.05 taken to be significantly 
different. Results: Post-treatment mean PCV on day 4 was significantly lower than day 
18 in all groups except AS group which had similar PCV all through evaluation. Although 
AQ had lowest mean PCV on day 4, by day 18, mean PCV returned to normal and hpt 
levels was significantly higher than AS and ASQ groups (p < 0.001). Hpt level (mean ± 
sem) for AS, ASQ, AQ, and control on day 18 were: 18.67 ± 0.004, 50.66 ± 0.014, 73.06 
± 0.003, and 74.13 ± 0.032 mg/dl respectively (p < 0.0001). On day 18, AS and ASQ 
had significantly lower Hpt level compared to day 4 (p <0.001). No neutropenia was 
observed during the study. Conclusion: Artesunate induces delayed hemolysis in 
malaria-free animals possibly through an oxidative toxic effect on the red blood cell 
membrane. Delayed post-treatment hemolysis was not observed with artesunate-
amodiaquine or amodiaquine alone. 
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Introduction  
Hemolysis, the immature destruction of red blood cells (RBC) at a rate that 
exceeds production of the RBC, commonly occurs in malaria infection. The 
causes of hemolysis is multifactorial, it may be a consequence of merozoite 
release from red blood cells, suppression of erythropoiesis by cytokines which 
are released along with, nutritional deficiencies, immunity, hemoglobinopathies 
or oxidative effects of drugs. In the food vacuole of malaria parasite, heme 
increases the activation of the endoperoxide moiety of the drug (Meshnick, 
1996) to generate reactive oxygen species, glutathione peroxidase and 
malondialdehyde which causes damage to the parasite membranes and proteins 
(Meshnick et al., 1989; Scott et al., 1989). The resulting degree of hemolysis 
depends on the duration and course of malaria infection (Price et al., 2001; Yeo 
et al., 2009).  
Artemisinin based combination treatments are the most rapidly acting and 
effective antimalarials for treatment of falciparum malaria (WHO, 2014). 
Artemisinin drugs are known to act by inducing oxidative stress after activation 
of the peroxide bridge which generates reactive metabolites (Meshnick, 1994); 
this is their major mechanism of killing malaria parasite. Despite generating 
oxidative radicals, artemsinins are known to conserve the red blood cells, this is 
demonstrable by moderate falls in hematocrit (Price et al., 2001; Obonyo et al., 
2007; Gbotosho et al., 2014) and presence of once infected red blood cells in 
circulation after parasite clearance  (Angus et al., 1997; Chotivanich et al., 2000; 
Newton et al., 2001). The red cell conservation by artemisinin drugs is however 
transient because the erythrocytes are eventually destroyed by the spleen 
leading to the “delayed post-artemisinin hemolytic” syndrome (DPAH).  
Delayed hemolysis was first recognized after parenteral artesunate in naïve 
patients, studies have also reported delayed hemolytic anemia after 
administration of oral artemisinin derivatives in immune and non-immune 
subjects with severe malaria or hyperparasitemia (WHO, 2013; 2014; CDC, 2014; 
Jaureguiberry et al., 2014; Rehman et al., 2014; Molta et al., 2003). Different 
hypothesis have been proposed to explain the underlying cause of hemolysis 
after artemisinin treatment, however the hypothesis that pitted erythrocytes are 
destroyed during recovery best explains post-artesunate delayed hemolysis after 
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treatment of malaria infection (Jaureguiberry et al., 2014). Hemolysis may occur 
after treatment with different classes of antimalarials (Price et al., 2001; Obonyo 
et al., 2001; Sumbele et al., 2010; Sowunmi et al., 2009), however studies have 
not reported delayed post-treatment hemolysis occurring with antimalarials 
other than artemisinin derivatives.  
This study aims to better understand the mechanism of post-delayed hemolytic 
effects of artemisinin and a commonly used partner drug – amodiaquine. This 
study evaluates post-artesunate or ACTs delayed hemolytic effects in uninfected 
animal model, providing a clear understanding of the mechanism of delayed 
hemolysis after antimalarial treatment.  
Materials - Methods 
Study design 
Forty female albino rats were weighed and divided randomly into five groups of 
eight animals each. There were 4 treatment groups (3 groups received 
antimalarials, 1 group received a known hemolytic drug) and one untreated 
group (control). Treatment outcomes were compared within treatment groups or 
with positive or normal control group.  
Drug treatment 
Two commercially available antimalarials were purchased and used for the study; 
200mg base amodiaquine (Camoquin®, Pfizer, USA) and 50mg artesunate 
(Artesunat®, Mekophar, Vietnam) and were crushed and dissolved in distilled 
water. Standard doses of the drugs were administered based on weight of the 
animals and given orally using cannula. Animals in group 1 received 4mg/kg 
body weight artesunate for 7 days (AS), group 2 received 10mg/kg amodiaquine 
(AQ) for 3 days, group 3 received 4mg/kg artesunate plus 10mg/kg 
amodiaquine (ASQ) for 3 days, group 4 received distilled water and served as 
normal control (Control) and group 5 received 1ml/kg phenylhydrazine for 1 day 
and served as positive control for hemolysis (PHZ).  
Animals 
The animals were purchased and housed separately per group; they were kept 
at room temperature in the animal house to acclimatize for one week. They were 
fed animal feeds ad-libitum and allowed free movement. All the animal 
experiments and handling were carried out following the standard ethics for 
Animal studies.  
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Laboratory tests 
Blood samples for hematological tests were collected by pricking the tail of the 
rat on day 0, 4 or 8 and 18 after treatment. The blood was collected in 
microhematocrit tubes and centrifuged at 12,000 x g for 5 minutes to determine 
packed cell volume (PCV). Post-treatment, half of the animals were sacrificed on 
the day of test; 3mls blood was collected through cardiac puncture under mild 
anesthesia using diethyl ether. The blood samples were collected into 
heparinized tubes or plain bottles and centrifuged at 12,000 x g for 15mins to 
obtain the serum and plasma. Blood for reticulocyte and white blood cell count 
was diluted with normal saline and fixed with methanol before counting.  
They were stained with Leishman, and counted against 1000 white blood cells 
using Naubauer hemocytometer under the microscope at magnification of x100. 
Differential count of the white blood cells was determined by absolute 
neutrophil, basophil, eosinophil, monocyte and reticulocytes count, thereafter 
the percentage of each was calculated from a total of 100 cells counted. 
Haptoglobin test was done on day 4 in half of the animals and on day 18 in the 
other half. Hemolysis was induced in group 5 by oral administration of 1ml/kg 
body weight of phenylhydrazine intravenously on day 4. This served as positive 
control for hemolysis. 
Haptoglobin assay  
Rat haptoglobin (Hpt) level was assayed using the biotin labelled ELISA kit 
(EASTBIOPHARM®) and was carried out according to manufacturer’s instructions 
as follows. Serum (40ul) sample was added to each Hpt pre-coated well, 
incubated with anti-Hpt antibody labeled with biotin or streptavidin-HRP at 37oC 
for 60 minutes. The reaction was terminated using chromogen reagent and 
absorbance was read on a microplate reader at 450nm wavelength and 
compared with standard. 
Hematological evaluation 
Hemolytic effects of drug treated groups were compared with normal control 
and positive control groups. Anemia was taken to be present if PCV value was 
<30% and hemolysis was present if Hpt level is very low or similar to that of 
positive control. Overall neutrophil counts lower than 100 (against 1000 WBC) 
was taken to indicate neutropenia. At recovery phase, hematological values in 
drug treated groups were compared with control groups to determine extent of 
hemolysis and recovery. 
Statistical Analysis 
The data was analyzed using the SPSS software version 16 (SPSS Inc., Chicago, 
USA). Graphs were done using excel or Graph pad prism software (Graphpad 
version 4.0, 1999). Values are reported as mean values ± standard error of mean 
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or proportions. Mean values were compared using t-test or ANOVA, followed by 
Duncan’s multiple range test, proportions were compared using chi-square test 
or fisher exact test, the level of significance was set at p<0.05.  
Results 
Before treatment, the weight range of the animals was between 170-250 g. The 
average weight of all animals on day 0 was 201.25 g and mean packed cell 
volume on day 0 was 48.1%. Severe hemolytic effects were not recorded in any 
animal. 
Packed cell volume 
Packed cell volume in all but 1 animal was >30% prior to treatment, this one 
animal was excluded from evaluation. Following treatment, anemia was not 
recorded in any animal. Table 1 shows the hematological outcomes in all 
groups. Post-treatment and recovery PCV values were similar in AS group (p = 
0.10). In ASQ and AQ groups, there was 28-38% fall in PCV by day 4 after 
treatment, this was significantly lower than PHZ group, however mean PCV on 
day 18 was significantly higher than day 4 (p < 0.03). In PHZ group, PCV 
continued to decline until day 18 (Fig. 1).  In ASQ and AQ, mean PCV on day 4 
was significantly lower than other treatment groups (p < 0.0001) (Fig. 1). After 
completion of treatment, mean PCV was significantly higher in AS than ASQ or 
AQ (p < 0.0001). PCV on day 18 in all groups was similar, but significantly higher 
than PHZ (p < 0.001) indicating full recovery from the moderate and non-severe 
hemolytic effects of the antimalarials. 
Figure 1. Mean packed cell volume in artesunate (AS), artesunate-
amodiaquine (ASQ), amodiaquine (AQ), and control (CTRL) groups of 
malaria-free rats.  
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Table 1. Hematological profiles of treated animals during the study 
Haptoglobin level 
In AS group, mean Hpt level on day 8 was 67.73 mg/dl, this was significantly 
higher than Hpt level on day 18 (18.67 mg/dl), p < 0.0001. In ASQ, mean Hpt 
level on day 4 (73.06 mg/dl) was significantly higher than day 18 (50.66 ± 0.013 
mg/d), p = 0.001 while in AQ group, mean haptoglobin level was significantly 
lower on day 4 (58.13mg/dl) than day 18 (73.46 mg/dl), p = 0.01. All treatment 
groups were compared with control at the recovery phase to determine delayed 
hemolysis. Hpt level (mean ± sem) for AS, ASQ, AQ, and control on day 18 were: 
18.67 ± 0.004 (n = 2), 50.66 ± 0.014 (n = 4), 73.06 ± 0.003 (n = 4), and 74.13 ± 
0.032 mg/dl (n = 3), respectively. There was a significantly lower Hpt level in AS 
and ASQ groups compared to AQ or control groups on day 18 (p <0.05) (Fig. 2). 
White Blood Cell Differential Count 
Total white blood cell (WBC) count on day 0 was within normal range (5 x 109/
mm3), this was similar in all groups at baseline, after treatment (day 4) and during 
recovery (day 18). Neutrophils were compared within and between groups to 
determine if neutropenia occurred following treatment and during recovery. 
Neutropenia and agranulocytosis was not observed. In AS and AQ groups, no 
significant difference was observed between day 4 and day 18 (p = 0.703). 
Overall, there was no significant difference in differential count observed in all 
groups compared to PHZ group.  
PCV (%) AS ASQ AQ PHZ Control P value
D0 
Mean ± sd (%) 52.4 ± 4.15 46.75 ± 1.70 47.25 ± 3.40 48.6 ± 4.08 46.2 ± 1.25 0.13
After treatment 
Mean ± sd (%) 52.5 ± 1.68 § 36. 0 ± 4.24* 35.5 ± 3.50* 45.0 ± 7.07 46.0 ± 6.25 <0.0001
At recovery  
Mean ± sd (%) 54.5 ± 0.71 59.5 ± 6.36 58.0 ± 7.01 40.0 ± 4.24** 60.0 ± 5.25 <0.0001
Neutrophil 
count D4 (%) 17 16 18 ND 14 -
Neutrophil 
count D18 (%) 17 19 15 ND 13 -
P value 
(within group) 0.10 0.0001 0.001 0.56 0.003 -
* Significantly lower than other treatment groups after treatment, ** significantly lower than other 
treatment groups at recovery, §evaluation done on D8, ND – not done
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Figure 2. Post-treatment haptoglobin levels in artesunate (AS), artesunate-
amodiaquine (ASQ), amodiaquine (AQ), and control on day 4 and 18 in 
malaria-free treated animals. 
Discussion 
The recent reports of delayed post-artemisinin hemolysis have brought to light 
the unrecognized burden of drug-induced hemolysis occurring especially after 
treatment of infections. Studies have reported immunosuppressive or inhibition 
of erythropoiesis (Yang et al., 2005; Wang et al., 2007; Finaurini et al., 2010), and 
other adverse effects of artemisinin derivatives both in the presence or absence 
of malaria parasites including hemolytic effects (Gu et al., 1986; Orjih, 1996; 
Garba and Ubom, 2005; Zhou et al., 2005; Anaba et al., 2012; Alzoubi et al., 
2014; Lee et al., 2015; Kurth et al., 2016), many of which appear to be non-
severe. The mechanism for inducing delayed post-artemisinin hemolysis when 
administered as monotherapy or co-administered with a partner drug such as 
amodiaquine remains to be understood.  Artemisinin-based combination 
treatments (ACTs) remains the preferred first-line and safe treatment of 
falciparum malaria because of its rapid clearance of parasitemia, and reduction 
of chances of deaths in cases of severe malaria (Sinclair et al., 2012). 
In the present study, animals in AQ and ASQ groups recovered from the 
hemolytic effects of all drug treatment. Packed cell volume and differential count 
by day 18 were similar compared to untreated animals. The lowest PCV values 
recorded on day 4 (after treatment) is a well explained phenomenon of drug 
induced hemolysis (Price et al., 2001; Sowunmi et al., 2009; Obonyo et al., 
2007). This lends support to findings from other studies reporting decrease in 
hematocrit level after treatment with ACTs (Price et al., 2001; Omotuyi et al., 
2008; Rolling et al., 2013; Gbotosho et al., 2014).  
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After completion of treatment, drug-attributable fall in hematocrit is common, 
this decline in hematocrit is attributable to the hemolytic effects of longer acting 
antimalarials (Price et al., 2001; Obonyo et al., 2007; Sowunmi et al., 2009). 
Haptoglobin is known to facilitate the removal of hemoglobin from the 
extravascular compartment via the CD163 macrophage scavenger receptor and 
is usually present in the presence of inflammation, or inflammatory diseases, or 
hemolysis to block hemoglobin-induced oxidative damage by forming 
haptoglobin-hemoglobin complex with decreased level reported in patients with 
acute inflammatory disease or hemolysis (Giffen et al., 2003; Rolling et al., 2013). 
Reduced serum haptoglobin observed in AS group on day 18 shows hemolysis 
occurred in the absence of malaria infection, although PCV level appeared 
normal.  
Surprisingly, delayed hemolysis did not occur in ASQ group, this could have 
been masked by the effects of amodiaquine in the combination. In the absence 
of malaria parasites, free iron bioactivation of the endoperoxide bridge of 
artemisinin drugs can be used to modulate its effects (Meshnick et al., 1989; 
1993; Meshnick, 1996; Krishna et al., 2004; Muhia et al., 1994; Meshnick, 1996; 
Tangnitipong et al., 2012; Conran, 2014). Delayed hemolysis in AS group follows 
a pattern similar to that reported in malaria infected persons (Eder et al., 2012; 
WHO, 2013; Arguin et al., 2014; Conran, 2014; Jauréguiberry et al., 2014; 
Rehman et al., 2014; Chavada et al., 2015; Boillat et al., 2015; Lee et al., 2015; 
Rolling et al., 2015; Kurth et al., 2016), although no anemia was recorded 
throughout this study.  
The mechanism of delayed hemolysis occurring in the absence of malaria 
parasite is likely due to toxic effects of artemisinin owing to generation of 
oxidative radicals. This can result in suppression of erythropoiesis (Yang et al., 
2005; Wang et al., 2007; Finaurini et al., 2010) and toxicity of the red cell 
membrane through generation of reactive species which induce oxidative stress 
causing  lipid peroxidation, gluthathione oxidation and oxidation of membrane 
protein thiols (Scott et al., 1989; Meshnick, 1996). Drug-induced oxidative stress 
worsens hemolysis in the presence of hemoglobinopathies or inadequate 
protection by the antioxidant defense system of the red blood cells which is 
often overwhelmed in disease states such as malaria. In the absence of the 
protective enzyme glucose-6-phosphate dehydrogenase; which maintains the 
supply of reduced glutathione used to mop up free radicals, oxidative damage 
of the vascular epithelium occurs (Ruwende and Hill, 1998; Jollow and McMillan, 
2001; Beutler et al., 2007; Chikezie et al., 2010; Vickers et al., 2010; Chikezie, 
2014). In this study, G6PD deficiency or other hemoglobinopathies cannot be 
implicated. 
Indeed studies have shown that oxidative stress precedes hemolysis of the red 
blood cells (Jollow and McMillan, 2001; Jeney et al., 2002) following a similar 
mechanism in both human and rats when exposed to highly oxidative 
compounds (Vickers et al., 2010). Shortened survival and removal of pitted 
erythrocytes explains only part of hemolysis in presence of malaria infection 
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(Arguin et al., 2014; Jaureguiberry et al., 2014; Rolling et al., 2015; Kurth et al., 
2016), unparasitized red blood cells are also cleared (Newton et al., 2001). 
Increased splenic clearance and lysis of the erythrocytes is also attributed to 
altered symmetry of phospholipid layer and reduced red cell deformability due 
to membrane rigidity caused by merozite invasion (Pasvol et al., 1992; Dorndorp 
et al., 2001; Cooke et al., 2004; Park et al., 2008; Nuchsongsin et al., 2008).  
In this study, the haptoglobin levels in all groups were moderately low by day 4, 
indicating potent hemolytic effect of both artesunate and amodiaquie. Clark et 
al. (1991) indicated that nitric oxide production increases in a state of infection 
such as malaria leading to poor deformability of red blood cells membrane. Free 
hemoglobin also depletes nitric oxide and increases oxidative inflammatory 
process. The nitric oxide is thought to inhibit Na+/K+ ATPase and causing 
oxidization of lipids in the red blood cell membrane through generation of 
peroxynitrate – a highly potent oxidant (Yeo et al., 2009). Most antimalarials 
reduce the deformability of the red blood cell membrane which makes the red 
cell rigid and unable to pass through the microcirculatory bed of the spleen, thus 
they are marked for splenic clearance (Dondorp et al., 2004). 
Drug induced hemolysis can be easily implicated in a case of multiple drug 
intake, because hemolysis could be triggered via immune complex formation 
with the drugs on RBC surface or auto-antibody production. In humans, other 
possible causes of hemolysis include genetic susceptibility such as 
polymorphisms in drug metabolizing enzymes – CYP2A6 (Roederer et al., 2011), 
hemoglobinopathies such G-6-P-D deficiency which is common in malaria 
endemic areas (Price et al., 2001; Beutler et al., 2007; Van Malderen et al., 2012; 
Howes et al., 2012) and suppressed erythropoiesis after administration of 
artemisinin, in the presence of other hemolytic factors such as malaria parasite, it 
would result in anemia as seen in hyperparasitemic individuals.  
The hypothesis that explains that post-artemisinin delayed hemolysis after 
treatment of malaria infection is attributable to eventual destruction of pitted 
erythrocytes which have a shortened lifespan (Clark, 2013; WHO, 2013; Arguin 
et al., 2014) could also explain the case with malaria-free animals in which case 
exposure to artemisinin drugs cause oxidative stress on the red cell membrane, 
thus a reduced lifespan or clearance by the spleen. Haptoglobin levels in the 
experimental animals indicate that hemolysis occurred during treatment in all 
groups but was more pronounced on day 18 in AS group. Although Hpt level 
observed in ASQ group was low, it was not as low as in artesunate-treated 
animals on day 18. Only 2 animals were evaluable in AS group on day 18, this 
may have accounted for a skewed value recorded for the group. 
Amodiaquine is implicated as a cause of neutropenia, which is characterized by a 
decrease in granular white blood cells after prolonged use for prophylaxis 
(Olliaro and Mussano, 2003). Our findings are in consonance with other reported 
animals studies (Omotuyi et al., 2008) and that observed in human treated with 
amodiaquine, they showed normal limits of hematological profile with no 
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agranulocytosis (Molta et al., 2003). Artesunate have been previously reported 
to be associated with neutropenia at doses higher than doses administered in 
our study (Bethell et al., 2010), however neutropenia was not observed with AS, 
ASQ or AQ during the study. This study lends support to a case report of 
artesunate induced auto-immune post-treatment delayed hemolysis, although 
this occurred in a malaria patient (Raffray et al., 2014).  
Limitations of the study 
Artesunate treatment was given for 7 days following recommendation for 
artesunate monotherapy while other treatments were administered for 3 days. 
This study did not evaluate delayed hemolysis after 3 days administration of 
artesunate to see if the outcome will differ from the reported result. Other 
antimalarial drug combinations were not evaluated for this study. Comparison 
was done in half of the animals in each group sacrificed after treatment and the 
remaining half at the end of the study. Thus these data were taken to be 
representative of the hemolytic effects occurring in individual animals. It is not 
known if this is the case. Lactate dehydrogenase assay was not done and no 
malaria infected group was evaluated along with the study groups, this group 
would have shown hemolysis during untreated malaria infection in mice.   
Conclusion 
Hemolysis occurred with all treatment in the absence of malaria parasites but 
rather occurred late; during recovery in AS and ASQ groups, PCV levels did not 
indicate hemolysis, > 30% anemia cut off but hpt levels were lower. This study 
reports that delayed post-artemisinin hemolysis can also occur in the absence of 
malaria parasites possibly through an oxidative toxic effect on the red blood cell 
membrane. There was no delayed hemolysis occurring after amodiaquine 
administration, rather hemolysis occurred immediately after completion of 
treatment.  
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Abbreviations 
RBC: red blood cells 
PCV: packed cell volume 
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ASQ: amodiaquine-artesunate 
ACTs: artemisinin-based combination treatment. 
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